home / stock / ipn / ipn news


IPN News and Press, SPDR S&P International Industrial Sector From 09/18/21

Stock Information

Company Name: SPDR S&P International Industrial Sector
Stock Symbol: IPN
Market: NYSE

Menu

IPN IPN Quote IPN Short IPN News IPN Articles IPN Message Board
Get IPN Alerts

News, Short Squeeze, Breakout and More Instantly...

IPN - Ipsen: ESMO 2021: Cabometyx Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx ® (cabozantinib). Of note, the final analysis of ...

IPN - Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire HAMILTON , ON and BOSTON , April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncol...

IPN - Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen Canada NewsWire Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Soli...

IPN - Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)

Ipsen (Euronext: IPN; ADR: IPSEY) announced today a total of 9 abstracts presenting new data with a focus in NETs. 1-10 These include data from the Phase II CLARINET FORTE study and data on the use of independent administration of lanreotide autogel to be presented at the ENETS Conf...

IPN - Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living With Renal Cell Carcinoma at ASCO GU 2021

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from its growing oncology portfolio will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place virtually from 11-13 February 2021. 11 A total ...

IPN - Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005966/en/ Gwenan White, Executive Vice President, Communications and Public Affairs, Ipsen (Photo: Business Wire) Ipsen (Euronext: IPN; AD...

IPN - Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing Canada NewsWire NEW YORK, March 26, 2020 NEW YORK , March 26, 2020 /CNW/ - Deutsche Bank today announced that the presentations from the March 18 th and 19...

IPN - Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

NEW YORK , March 26, 2020 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the March 18 th and 19 th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companie...

IPN - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 Canada NewsWire NEW YORK, March 10, 2020 NEW YORK , March 10, 2020 /CNW/ - Deutsche Bank today announced the lineup for its Deposi...

IPN - Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer Canada NewsWire MONTREAL, Sept. 10, 2019 ...

Previous 10 Next 10